Endocrine Abstracts

Introduction: GH rises dose dependently during treatment with the GH receptor antagonist pegvisomant. Ghrelin stimulates GH secretion. In de novo acromegalic patients with high GH levels, ghrelin levels are lowered and fat mass is reduced. Leptin levels are positively correlated to fat mass. We performed this cross-sectional study to evaluate whether elevated endogenous GH in acromegalic patients on pegvisomant treatment (peg) reduces ghrelin and leptin levels.<p class="ab...